Immunic

IMUXPhase 3

Immunic is focused on developing next-generation, orally available small molecule therapies that aim to address the underlying mechanisms of chronic inflammatory and autoimmune diseases with high unmet need. The company's strategy centers on its lead asset, vidofludimus calcium (IMU-838), a selective oral immunomodulator targeting DHODH, which is in Phase 3 for multiple sclerosis and Phase 2 for ulcerative colitis and Crohn's disease. With a public listing and a diversified pipeline, Immunic aims to bring novel, convenient treatment options to patients suffering from debilitating autoimmune conditions.

Market Cap

$143.5M

Employees

50-100

Focus

Biotech

IMUX · Stock Price

USD 1.1010.65 (-90.64%)

Historical price data

AI Company Overview

Technology Platform

Oral small molecule platform focused on selective immunomodulation, primarily through inhibition of the dihydroorotate dehydrogenase (DHODH) enzyme to target overactive lymphocytes in autoimmune diseases.

Pipeline Snapshot

8 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
IMU-838 tablets + Placebo matching IMU-838 tablets	Multiple Sclerosis	Phase 3
IMU-838 tablets + Placebo matching IMU-838 tablets	Multiple Sclerosis, Relapsing-Remitting	Phase 3
IMU-838	COVID-19	Phase 2/3
IMU-838 + Placebo	Ulcerative Colitis	Phase 2
IMU-838 + Oseltamivir	Covid 19	Phase 2

Opportunities

Immunic's primary growth opportunity lies in successfully developing and commercializing vidofludimus calcium as a best-in-class oral therapy for multiple sclerosis and inflammatory bowel disease, multi-billion dollar markets dominated by injectable drugs.

The novel mechanism of IMU-856 for intestinal barrier repair represents a first-in-class opportunity in Crohn's disease.

Risk Factors

The company faces high clinical risk with its lead asset in pivotal trials, intense competition from large pharmaceutical companies with established products, and dependence on raising additional capital to fund operations as a pre-revenue entity.

Competitive Landscape

Immunic competes in crowded markets against major players like Roche, Novartis, and Bristol Myers Squibb in MS, and against biologics and JAK inhibitors in IBD. Its differentiation strategy is based on the oral DHODH inhibition mechanism of vidofludimus calcium, aiming for a favorable efficacy-safety profile compared to existing oral and injectable therapies.